Skip to content

Study · Non-randomized trial · n = 17 · 2022

2 results

Natural History of Obesity Due to POMC, PCSK1, and LEPR Deficiency and the Impact of Setmelanotide.

Wabitsch M, Farooqi S, Flück CE, Bratina N, Mallya UG, Stewart M, Garrison J, van den Akker E, Kühnen P

Journal of the Endocrine Society15 Apr 2022Cited by 49 (Europe PMC)

PMID35528826 (opens in a new tab)PMCIDPMC9070354 (opens in a new tab)DOI10.1210/jendso/bvac057 (opens in a new tab)PepBankPUB-35528826
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with POMC, PCSK1 or LEPR deficiency, setmelanotide attenuated the weight trajectory over a 1 year observation period.

    In plain wordsIn patients with POMC, PCSK1 or LEPR deficiency, weight gain slowed during setmelanotide over a 1 year observation period.

    Peptide
    Setmelanotide
    Outcome
    DecreaseWeight trajectory
    Study

    n = 17

    Comparator
    patients' own historical pre-treatment weight trajectory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide treatment attenuated weight and body mass index trajectories over the observation period of 1 year.
    3 context sentences
    Summary · context
    This analysis included data from 2 pivotal single-arm, open-label, Phase 3 trials (NCT02896192, NCT03287960).
    Summary · context
    Patients had obesity due to POMC/PCSK1 or LEPR deficiency.
    Summary · context
    During the trial, patients were treated with setmelanotide.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with POMC, PCSK1 or LEPR deficiency, setmelanotide attenuated the body mass index trajectory over a 1 year observation period.

    In plain wordsIn patients with POMC, PCSK1 or LEPR deficiency, body mass index increases slowed during setmelanotide over a 1 year observation period.

    Peptide
    Setmelanotide
    Outcome
    DecreaseBody mass index trajectory
    Study

    n = 17

    Comparator
    patients' own historical pre-treatment BMI trajectory
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Setmelanotide treatment attenuated weight and body mass index trajectories over the observation period of 1 year.
    3 context sentences
    Summary · context
    This analysis included data from 2 pivotal single-arm, open-label, Phase 3 trials (NCT02896192, NCT03287960).
    Summary · context
    Patients had obesity due to POMC/PCSK1 or LEPR deficiency.
    Summary · context
    During the trial, patients were treated with setmelanotide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.